|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Zen-Bio, Inc. Awarded $961,000 Grant From National Institutes of Health (NIH); Proceeds To Fund The Development Of A Human Omental Adipocyte (Fat) Cell System Useful In The Discovery Of The Next Generation Cures And Diagnostic Tools For Obesity Related Diseases
10/19/2005 5:12:28 PM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Sept. 21, 2005--Zen-Bio, Inc, a private closely held biotechnology company, today announced that it was awarded a 24 month $961,578 Phase II SBIR grant from the National Institutes of Health. The phase II application was awarded after the successful completion of Zen-Bio's $100,000 NIH Phase I award. The phase II grant was favorably reviewed by the NIH for both scientific merit and business strategy.
The grant will be used to fund the development and characterization of a human omental adipocyte cell system. "The human omental cell system is a novel research tool invaluable to human metabolic disease researchers," states Dr. Renee Lea-Currie, Zen- Bio's Director of Cell Biology and the grant's Principal Investigator. She went on to state, "Customers will be able to use our human cell system to evaluate potential new drugs and therapies as well as elucidate some of the basic functions of this highly metabolically active endocrine organ."
|
|
|
|
|
|
|
|
|
|
|